Stocks did just enough this week to keep the positive momentum going. GDP was better than expected, while geopolitical news was balanced (the North Korean summit ended without a deal, but the administration continues to hold out carrots to investors, hinting that a China trade deal is nearing). Behind the scenes, the Biotech sector had a standout week particularly for investors like us who favor the small-cap end of the scale.
Headlines this Week
- U.S. GDP quarter-on-quarter growth dropped from 4.2% in Q2 to 2.6% in Q4 as the sugar high from last year’s tax cuts wore off. However, the year-on-year growth of 3.1% paints a picture of steady economic progress. When combined with wage growth, which is finally outpacing price inflation, the economic picture remains robust.
- The global index provider MSCI, announced this Thursday that it would increase the weighting of China A-shares from 5 to 20 percent in three steps to November of this year. The exposure to the second largest economy is heavily underrepresented in the global indices (based on relative GDP). The change by index provider MSCI will likely bring over $60 billion in inflows to the Chinese A-share stock market… perhaps just in time for a U.S.-China trade deal?
- The UK’s Prime Minister Theresa May pushed back the vote in Parliament further, giving herself some time to gain more support for the Brexit deal. While the vote delay may help May, the party members against Brexit are calling for a second referendum.
- In his testimony to Congress, Fed Chairman Jerome Powell reassured investors that the U.S. economy remains on solid footing. Powell sighted meaningful wage and inflation growth and intention to pause rate increases amidst signs of economic slowdown in Europe and China.
The Week Ahead
- The ECB will make its rate decision Thursday, with no change expected
- Friday’s non-Farm Payroll always garners attention, with expectations for 180K jobs created
- Earnings are due out from a pair of retailers, Costco (COST) and DollarTree (DLTR)
- Speech Circuit: Due to speak are the Bank of England Governor Carney, Bank of Japan’s Harda, and the U.S. Federal Reserve’s Williams.
Stock Highlights from Max
The Health Care sector was tripped up this week thanks to a Medicaid for All Act proposed in Congress. The proposed law spooked not only the insurers and providers but also Healthcare REITs. Since our lone REIT exposure is in the Healthcare space, our REITs sector was the biggest laggard. The Technology sector was the leading sector, edging out both Energy and Communication Services by a slim margin. Speaking of tripping…
- Booking Holding Inc. (BKNG), operator of travel sites priceline.com, booking.com, kayak.com and many others, reported a sizeable earnings beat, despite a slight miss on revenue, but was tripped up by a guidance cut for next quarter. The guidance cut was unwelcomed by investors and masked a healthy gross booking increase of 9% in the quarter and a 13% increase in room nights. The clear takeaway was that events in Europe are weighing on the Euro-centric travel company. The market has now narrowed the valuation gap between Booking and fellow Strategic Growth travel stock Expedia, Inc. (EXPE), its closest competitor.
- TJX Companies Inc. (TJX), a retailer under the brands Marshall’s, TJ Maxx and Home Goods, also reported earnings this week. Earnings were in-line with expectations and sales came in a bit better. But the company offered up a dividend hike and a boost to its share buyback on top of 6% higher sales in the holiday quarter this past year versus the previous year.
|Indices & Price Returns||Week (%)||Year (%)|
|S&P 400 (Mid Cap)||-0.4||15.8|
|Russell 2000 (Small Cap)||0.0||17.9|
|MSCI EAFE (Developed International)||0.2||8.9|
|MSCI Emerging Markets||-0.7||8.8|
|S&P GSCI (Commodities)||-0.7||13.9|
|MSCI U.S. REIT Index||-1.9||11.5|
|Barclays Int Govt Credit||-0.3||0.4|
|Barclays US TIPS||-0.5||1.1|
Founded in 1979, Strategic is a leading investment and wealth management firm managing and advising on client assets of over $1.8 billion.Overview
Strategic Financial Services, Inc. is a SEC-registered investment advisor. The term “registered” does not imply a certain level of skill or training. “Registered” means the company has filed the necessary documentation to maintain registration as an investment advisor with the Securities and Exchange Commission.
The information contained on this site is for informational purposes and should not be considered investment advice or a recommendation of any particular security, strategy or investment product. Every client situation is different. Strategic manages customized portfolios that seek to properly reflect the particular risk and return objectives of each individual client. The discussion of any investments is for illustrative purposes only and there is no assurance that the adviser will make any investments with the same or similar characteristics as any investments presented. The investments identified and described do not represent all of the investments purchased or sold for client accounts. Any representative investments discussed were selected based on a number of factors including recent company news or earnings release. The reader should not assume that an investment identified was or will be profitable. All investments contain risk and may lose value. There is no assurance that any investments identified will remain in client accounts at the time you receive this document.
Some of the material presented is based upon forward-looking statements, information and opinions, including descriptions of anticipated market changes and expectations of future activity. Strategic Financial Services believes that such statements, information, and opinions are based upon reasonable estimates and assumptions. However, forward-looking statements, information and opinions are inherently uncertain and actual events or results may differ materially from those reflected in the forward-looking statements. Therefore, undue reliance should not be placed on such forward-looking statements, information and opinions.
No content on this website is intended to provide tax or legal advice. You are advised to seek advice on these matters from separately retained professionals.
All index returns, unless otherwise noted, are presented as price returns and have been obtained from Bloomberg. Indices are unmanaged and cannot be purchased directly by investors.